Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Adverse effects
Systematic review	422 people 7 RCTs in this analysis	At least 1 adverse effect with clozapine (25–700 mg/day) with olanzapine (5–50 mg/day) Absolute results not reported	RR 0.72 95% CI 0.53 to 0.97	Small effect size	olanzapine
Systematic review	1445 people 7 RCTs in this analysis	Sedation with clozapine (25–900 mg/day) with olanzapine (5–50 mg/day) Absolute results not reported	RR 0.61 95% CI 0.39 to 0.95	Small effect size	olanzapine
Systematic review	1097 people 4 RCTs in this analysis	Seizures with clozapine (150–900 mg/day) with olanzapine (5–50 mg/day) Absolute results not reported	RR 0.15 95% CI 0.04 to 0.58	Large effect size	olanzapine
Systematic review	1320 people 4 RCTs in this analysis	Akathisia with clozapine (100–900 mg/day) with olanzapine (5–50 mg/day) Absolute results not reported	RR 1.37 95% CI 0.71 to 2.63		Not significant
Systematic review	327 people 2 RCTs in this analysis	Dyskinesia with clozapine (100–600 mg/day) with olanzapine (5–25 mg/day) Absolute results not reported	RR 2.29 95% CI 0.81 to 6.45		Not significant
Systematic review	327 people 2 RCTs in this analysis	Parkinsonism with clozapine (100–600 mg/day) with olanzapine (5–25 mg/day) Absolute results not reported	RR 0.78 95% CI 0.30 to 2.00		Not significant
Systematic review	980 people Data from 1 RCT	Rigor with clozapine (200–900 mg/day) with olanzapine (5–20 mg/day) Absolute results not reported	RR 6.0 95% CI 0.73 to 49.65		Not significant
Systematic review	561 people 6 RCTs in this analysis	Use of antiparkinsonian medication with clozapine (25–900 mg/day) with olanzapine (2.5–50 mg/day) Absolute results not reported	RR 1.14 95% CI 0.60 to 2.19		Not significant
Systematic review	1264 people 4 RCTs in this analysis	Significant low white blood cell count with clozapine (150–900 mg/day) with olanzapine (5–40 mg/day) Absolute results not reported	RR 0.18 95% CI 0.08 to 0.41	Large effect size	olanzapine
Systematic review	120 people Data from 1 RCT	Mean difference in change from baseline in prolactin (ng/mL) with clozapine (200–600 mg/day) with olanzapine (15–25 mg/day) Absolute results not reported	Mean difference 0.57 ng/mL 95% CI 0.09 ng/mL to 1.05 ng/mL	Effect size not calculated	clozapine
Systematic review	47 people 2 RCTs in this analysis	Mean difference in change from baseline in prolactin (ng/mL), men only with clozapine (50–800 mg/day) with olanzapine (10–40 mg/day) Absolute results not reported	Mean difference +8.65 ng/mL 95% CI –3.26 ng/mL to +20.55 ng/mL		Not significant
Systematic review	1600 people 7 RCTs in this analysis	Weight gain with clozapine (25–900 mg/day) with olanzapine (5–40 mg/day) Absolute results not reported	RR 1.13 95% CI 0.70 to 1.81		Not significant
Systematic review	581 people 7 RCTs in this analysis	Mean difference in change from baseline in weight (kg) with clozapine (25–900 mg/day) with olanzapine (2.5–50 mg/day) Absolute results not reported	Mean difference +0.04 kg 95% CI –0.97 kg to +1.06 kg		Not significant
Systematic review	980 people Data from 1 RCT	Death — suicide attempt with clozapine (200–900 mg/day) with olanzapine (5–20 mg/day) Absolute results not reported	RR 1.78 95% CI 1.22 to 2.62	Small effect size	clozapine
Systematic review	993 people 2 RCTs in this analysis	Death — suicide with clozapine (200–900 mg/day) with olanzapine (5–50 mg/day) Absolute results not reported	RR 0.6 95% CI 0.14 to 2.50		Not significant
Systematic review	180 people Data from 1 RCT	Extrapyramidal symptoms with clozapine (290–600 mg/day) with olanzapine (22 mg/day) Absolute results not reported	RR 0.44 95% CI 0.14 to 1.39		Not significant
Systematic review	Number of people unclear	Nausea with clozapine (290–600 mg/day) with olanzapine (22 mg/day) Absolute results not reported	RR 0.10 95% CI 0.01 to 0.77	Large effect size	olanzapine